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ABSTRACT
Introduction: Type2diabetes (T2D) is the leading
cause of chronic kidney disease (CKD). The
recommended dose of the dipeptidyl peptidase-4
inhibitor saxagliptin is 2.5 mg in patients with
moderate or severe renal impairment (creatinine
clearance B50 mL/min). In this post hoc analysis,
we assessed the effect of saxagliptin 2.5 and
5 mg/day versus placebo on glycemic measures in
patients with T2D and estimated glomerular
filtration rate 45–60mL/min/1.73 m2.
Methods: Efficacy and safety data were pooled
from nine 24-week, randomized,
placebo-controlled clinical trials.
Results: The majority (56–61%) of patients
were women aged \65 years with glycated
hemoglobin (A1C) 8.1–8.2%; half of the
patients had a T2D duration C5 years. Mean
change from baseline in A1C was significantly
greater with saxagliptin 2.5 (–0.6%, P = 0.036 vs
placebo) and 5 mg/day (–0.9%, P\0.001 vs
placebo) compared with placebo (–0.2%).
There were numerically greater reductions in
fasting plasma glucose and 2-h postprandial
glucose, and a significantly greater proportion
of patients achieved A1C\7% with saxagliptin
5 mg/day (44.8%) compared with placebo
(20.0%, P = 0.004 vs placebo). The incidence
of hypoglycemia was not significantly different
across groups (16.2% in the saxagliptin
5-mg/day, 12.2% in the saxagliptin
2.5-mg/day, and 11.3% in the placebo groups).
Conclusion: These results suggest that
saxagliptin 2.5 and 5 mg/day improve glycemic
control and are generally well tolerated in
patients with T2D and moderate CKD.
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INTRODUCTION
Worldwide, diabetes is the leading cause of
chronic kidney disease (CKD) [1], which is
defined by an estimated glomerular filtration
rate (eGFR) of \60 mL/min/1.73 m2 or an
albumin/creatinine ratio C30 mg/g for more
than 3 months [2]. In the United States, the
prevalence of CKD among individuals with
diabetes is estimated to be *40% based on
eGFR and/or albuminuria [3]. A recent analysis
of the National Health and Nutrition
Examination Survey (1999–2012) database
reported that 12.9% of patients with type 2
diabetes (T2D) had eGFR in the upper range of
moderate CKD (stage 3a: 45 to \60 mL/min/
1.73 m2) [4].
Treatment of patients with T2D and CKD is
challenging because many antidiabetes
medications are cleared by the kidneys and
require dosage adjustment to avoid
hypoglycemia [5]. Saxagliptin is a dipeptidyl
peptidase-4 inhibitor that improves glycemic
control in patients with T2D as monotherapy or
in combination with other antidiabetes
medications and imparts a very low risk of
hypoglycemia [6–14]. Saxagliptin is
metabolized to an active metabolite by the
liver and, along with the parent molecule, is
eliminated mainly by the kidney [15].
Therefore, the recommended dose of
saxagliptin is 2.5 mg/day in patients with
moderate or severe renal impairment
(creatinine clearance [CrCl] B50 mL/min),
which is half the recommended dose
(5 mg/day) for patients with normal kidney
function [16]. The objective of this post hoc
analysis was to assess the efficacy and safety of
saxagliptin 2.5 and 5 mg/day versus placebo
using data pooled from saxagliptin clinical trials
in patients with T2D and moderate renal
impairment (eGFR 45–60 mL/min/1.73 m2).
METHODS
Efficacy and safety data were pooled from nine
24-week, randomized, placebo-controlled
clinical trials, which included 4 trials of
saxagliptin monotherapy (NCT00121641 [6],
NCT00316082 [7], NCT00698932 [8], and
NCT00918879 [9]), 2 trials of saxagliptin
add-on to metformin (NCT00121667 [10]
and NCT00661362 [11]), and 1 trial each of
saxagliptin add-on to glyburide
(NCT00313313 [12]), add-on to a
thiazolidinedione (NCT00295633 [13]), and
add-on to insulin with or without metformin
(NCT00757588 [14]). Study designs and
inclusion and exclusion criteria have been
previously reported in detail [6–14]. Only
patients with eGFR of 45–60 mL/min/1.73 m2
at baseline were included in this analysis.
eGFR was calculated from serum creatinine
using the Modification of Diet in Renal
Disease equation [17]. Safety was assessed by
adverse events (AEs), serious AEs (SAEs), and
laboratory values.
Differences in changes from baseline in
glycated hemoglobin (A1C), fasting plasma
glucose (FPG), and 2-h postprandial glucose
(PPG) following an oral glucose tolerance test
were assessed using an analysis of covariance
model with treatment as the factor, baseline
value as the covariate, and study as the random
effect for the saxagliptin versus the placebo
groups. The proportion of patients achieving
A1C\7% at the end of the 24-week treatment
period was analyzed using the
Cochran–Mantel–Haenszel general association
test stratified by study. The incidence of
hypoglycemia with saxagliptin compared with
placebo was assessed by Fisher exact test.
Statistical analyses were performed with
Statistical Analysis System (SAS) software (SAS
Institute, Cary, NC, USA).
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Compliance with Ethics Guidelines
All procedures were in accordance with the
ethical standards of the responsible committee
on human experimentation (institutional and
national) and with the Helsinki Declaration of
1964, as revised in 2013. Informed consent was
obtained from all patients for inclusion in the
study. This article is based on previously
conducted studies and does not involve any
new studies of human or animal subjects
performed by any of the authors.
RESULTS
A total of 188 patients with eGFR
45–60 mL/min/1.73 m2 at baseline were
identified. The majority of patients were white
women\65 years old with a mean baseline A1C
of 8.1–8.2% and a mean T2D duration of
6.5–8.6 years (Table 1). Mean eGFR at baseline
was 54–55 mL/min/1.73 m2. Demographics and
baseline characteristics were similar across
treatment groups.
At 24 weeks, the mean change from baseline
in A1C was significantly greater with saxagliptin
2.5 mg/day (mean [95% CI] difference from
placebo –0.6% [–0.8%, –0.0%]; P = 0.036) and
5 mg/day (–0.9% [–1.0%, –0.4%]; P\0.001)
compared with placebo (Fig. 1a). There were
numerically greater, but not statistically
significant, reductions from baseline in FPG
(Fig. 1b; mean [95% CI] difference from placebo
2.5 mg/day, –10 [–21.7, 10.2] mg/dL; 5 mg/day,
–16 [–27.7, 1.9] mg/dL) and 2-h PPG (Fig. 1c;
mean [95% CI] difference from placebo
2.5 mg/day, -48.6 [–51.4, 8.4] mg/dL;
5 mg/day, -57.7 [–47.0, 8.8] mg/dL) with
saxagliptin 2.5 and 5 mg/day compared with
placebo. A greater proportion of patients
Table 1 Demographics and baseline characteristics of patients with eGFR 45–60 mL/min/1.73 m2






Age, years 62.9 (7.1) 63.4 (7.9) 61.8 (9.3)
Women, n (%) 40 (56) 30 (61) 41 (60)
Race, n (%)
White 46 (65) 43 (88) 47 (69)
Black 1 (1) 2 (4) 1 (2)
Asian 23 (32) 4 (8) 19 (28)
Other 1 (1) 0 1 (2)
BMI, kg/m2 29.8 (4.8) 30.5 (4.7) 30.1 (5.5)
Duration of T2D, years 8.6 (8.4) 6.5 (7.0) 7.1 (7.5)
A1C, % 8.2 (0.95) 8.1 (0.81) 8.1 (0.91)
eGFR, mL/min/1.73 m2 55.2 (3.9) 54.2 (4.6) 55.3 (3.6)
Data are mean (SD) unless otherwise noted
A1C glycated hemoglobin, BMI body mass index, eGFR estimated glomerular ﬁltration rate, SD standard deviation, T2D
type 2 diabetes
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Fig. 1 Mean change from baseline to week 24 in a A1C, b FPG, and c 2-h PPG. A1C glycated hemoglobin, FPG fasting
plasma glucose, NS nonsigniﬁcant, PPG 2-h postprandial glucose, SAXA saxagliptin, SD standard deviation
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achieved A1C\7% at week 24 with saxagliptin
2.5 mg/day (34.7%, NS) and 5 mg/day (44.8%,
P = 0.004 vs placebo) compared with placebo
(20.0%; Fig. 2).
Overall, AEs were reported more frequently
with saxagliptin treatment compared with
placebo (Table 2). AEs and SAEs related to
kidney function were infrequent. The
proportion of patients with increased blood
creatinine was generally similar with placebo
(5.6%) and saxagliptin treatment (4.4–8.2%).
There was 1 SAE of acute renal failure in the
saxagliptin 2.5-mg/day group and none in the
saxagliptin 5-mg/day and placebo groups. The
61-year-old woman was overweight and had a
history of hypertension, hypercholesterolemia,
hypertriglyceridemia, and probable baseline
CKD exacerbated by relative volume depletion
and concomitant medications. Saxagliptin was
discontinued, and the event resolved following
treatment. The acute renal failure was
considered unlikely to be related to
saxagliptin. In general, AEs were similar with
saxagliptin 2.5 and 5 mg/day, although AEs
related to pain were more frequent with
saxagliptin 5 than 2.5 mg/day. The proportion
of patients with hypoglycemia was numerically
greater, but not significantly different,
compared with placebo (11.3%) in the
saxagliptin 2.5-mg/day (12.2%, P = 1.000) and
5-mg/day groups (16.2%, P = 0.464). At
24 weeks, there were small mean increases in
eGFR from baseline in all treatment groups
(Fig. 3).
DISCUSSION
Impaired renal function is common in patients
with T2D, especially in those C65 years [4], and
is independently associated with increased
mortality, cardiovascular events, and
hospitalization [18, 19]. Pharmacotherapy in
patients with T2D can be challenging and
therapeutic options may be limited because a
reduced GFR results in the accumulation of
certain drugs and/or their metabolites that may
increase the risk of side effects or hypoglycemia
[5, 20]. In this analysis of patients with T2D and
moderate CKD, saxagliptin 2.5 and 5 mg/day
significantly reduced A1C and resulted in
numerically larger reductions in FPG and PPG
compared with placebo. In addition, saxagliptin
5 mg/day doubled the proportion of patients
achieving A1C\7% after 24 weeks of treatment
compared with placebo. These improvements in
glycemic control with saxagliptin 2.5 and
5 mg/day were accompanied by small increases
in overall AEs and SAEs compared with placebo,
but AEs related to renal function were
infrequent and episodes of hypoglycemia were
generally similar across treatment groups. Of
note, eGFR remained stable over the 24 weeks of
treatment with saxagliptin as well as with
placebo.
Our results using data pooled from 9
randomized clinical trials of saxagliptin 2.5
and 5 mg/day are in agreement with the
results of a previously reported 12-week
Fig. 2 Proportion of patients achieving A1C\7% at week
24. A1C glycated hemoglobin, NS nonsigniﬁcant, SAXA
saxagliptin
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clinical trial [21] with an extension to 52 weeks
[22] of saxagliptin 2.5 mg/day (plus background
antidiabetes medications) in patients with T2D
and moderate (CrCl 30 to\50 mL/min), severe
(CrCl\30 mL/min and not receiving
hemodialysis), or end-stage (receiving
hemodialysis) kidney disease. In that study,
saxagliptin was well tolerated across all stages
of CKD and reduced A1C, compared with
placebo, in patients with moderate and severe
CKD.
Limitations of this study include its post hoc
nature, relatively small number of patients, and
duration of 24 weeks. However, the results of
Table 2 Adverse events









C1 AE 46 (64.8) 41 (83.7) 51 (75.0)
C1 SAE 5 (7.0) 6 (12.2) 6 (8.8)
Most common AEs (C5%)
Urinary tract infection 6 (8.5) 6 (12.2) 6 (8.8)
Inﬂuenza 5 (7.0) 5 (10.2) 7 (10.3)
Nasopharyngitis 3 (4.2) 4 (8.2) 4 (5.9)
Pharyngitis 4 (5.6) 4 (8.2) 2 (2.9)
Upper respiratory infection 4 (5.6) 4 (8.2) 4 (5.9)
Bronchitis 4 (5.6) 3 (6.1) 2 (2.9)
Arthralgia 4 (5.6) 6 (12.2) 2 (2.9)
Back pain 3 (4.2) 2 (4.1) 5 (7.4)
Pain in extremity 3 (4.2) 1 (2.0) 5 (7.4)
Musculoskeletal pain 1 (1.4) 0 4 (5.9)
Diarrhea 0 3 (6.1) 3 (4.4)
Dyspepsia 3 (4.2) 3 (6.1) 2 (2.9)
Headache 2 (2.8) 2 (4.1) 4 (5.9)
Increased blood creatinine 4 (5.6) 4 (8.2) 3 (4.4)
Pruritus 0 3 (6.1) 0
Peripheral edema 4 (5.6) 2 (4.1) 4 (5.9)
Hypertension 6 (8.5) 4 (8.2) 3 (4.4)
Hypotension 0 3 (6.1) 1 (1.5)
Dyslipidemia 4 (5.6) 2 (4.1) 1 (1.5)
Hypoglycemia 8 (11.3) 6 (12.2) 11 (16.2)
AE adverse event, SAE serious adverse event
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this analysis are consistent with a recently
published subgroup analysis of the large
saxagliptin cardiovascular outcomes trial
Saxagliptin Assessment of Vascular Outcomes
Recorded in Patients With Diabetes Mellitus
(SAVOR) (ClinicalTrial.gov identifier,
NCT01107886) [23]. In that analysis, patients
were stratified according to baseline eGFR as
having normal or mildly impaired renal
function (eGFR [50 mL/min/1.73 m2,
n = 13,916), moderate renal impairment (eGFR
30–50 mL/min/1.73 m2, n = 2240), or severe
renal impairment (eGFR \30 mL/min/1.73 m2,
n = 336). Compared with placebo, saxagliptin
(5 or 2.5 mg/day in patients with eGFR
B50 mL/min/1.73 m2) significantly reduced
A1C in all eGFR subgroups at 1 year, which
persisted through a median follow-up of 2 years.
Saxagliptin also significantly reduced
progressive microalbuminuria in patients with
normal or mildly reduced renal function
(P\0.0001) and in those with
moderate-to-severe renal impairment
(P = 0.04) based on improvement or less
worsening of urinary albumin:creatinine ratio
compared with placebo [23].
CONCLUSION
In conclusion, saxagliptin at doses of 2.5 or
5 mg/day was equally well tolerated and
improved glycemic control in patients with
moderate renal impairment who have limited
treatment options.
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